NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Royalty Pharma PLC RPRX
8 fiscal years on record · USD · FY2025 reported · SEC filings only
4 YEARS OF DIVIDEND GROWTH
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
USD 2.4B
Revenue, FY2025 · full 8-year series below
Revenue $B
Net income $B
FY2025 · Revenue 2.4 · Net income 0.8
1B2B
2018202120242025
Compound annual growth
+2.1%
+2.3%
+162.1%
−4.6%
+161.1%
+6.2%
+7.3%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +2.3% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
56 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 65.6% · Net 55.7%
50%100%
201820212025
ROE
FY2025 · ROE 7.7%
20%40%
201820212025
Three returns, three denominators.
Each USD of equity produced 8 cents of profit this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 2.4 | 2.3 | 2.4 | 2.2 | 2.3 | 2.1 | 1.8 | 1.8 |
| Operating income $B | 1.6 | 1.3 | 1.5 | 0.3 | 1.4 | 1.6 | 2.6 | 1.4 |
| EBITDA $B | 1.6 | 1.3 | 1.5 | ◌ | ◌ | ◌ | ◌ | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income $B | 0.8 | 0.9 | 1.1 | 0.0 | 0.6 | 1.0 | 2.3 | 1.4 |
| EPS, diluted $ | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 | 1.32 | ◌ | ◌ |
| Dividend / sh $ | ◌ | 0.84 | 0.80 | 0.76 | 0.68 | 0.30 | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — |
| ROE % | 7.7 | 8.4 | 11.6 | 0.4 | 6.2 | 12.2 | 43.9 | 30.3 |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 0 failures in 28 reconciliationsAUDITED
Reconciled in 8 of the 8 fiscal years we could check. 24 checks were skipped: the balance sheet is not tagged before 2019. 13 checks were skipped: EPS is not tagged before 2020.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code X0
Fiscal year endsDecember 31
Data on record since2018